About: Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19
Creator	Liu, Jing Sun, Ruilin Wang, Zhaoqin Hong, Zhongsi Huang, Mingxing Xia, Jinyu Li, Man Shan, Hong Pei, Duanqing Zhong, Nanshan Li, Yang Hong, Wenxin Xiao, Fei Wang, Xiaohua Tang, Meiwen Tian, Lin Jiang, Guanmin Li, Zhonghe Zhou, Jianhui Lin, Changqing Chen, Binghui Chen, Huili Feng, Jianhua He, Songmei Jiang, Shanping Li, Yaocai Liang, Jiabi Liu, Shaoxuan Pang, Pengfei Shu, Jingxian Tang, Tiantian Wu, Zhilong Xiang, Jingfen Ye, Yinong You, Yingying Zhong, Bei
Source	PMC
abstract	BACKGROUND: Effective therapies are urgently needed for the SARS-CoV-2 pandemic. Chloroquine has been proved to have antiviral effect against coronavirus in vitro. In this study, we aimed to assess the efficacy and safety of chloroquine with different doses in COVID-19. METHOD: In this multicenter prospective observational study, we enrolled patients older than 18 years old with confirmed SARS-CoV-2 infection excluding critical cases from 12 hospitals in Guangdong and Hubei Provinces. Eligible patients received chloroquine phosphate 500 mg, orally, once (half dose) or twice (full dose) daily. Patients treated with non-chloroquine therapy were included as historical controls. The primary endpoint is the time to undetectable viral RNA. Secondary outcomes include the proportion of patients with undetectable viral RNA by day 10 and 14, hospitalization time, duration of fever, and adverse events. RESULTS: A total of 197 patients completed chloroquine treatment, and 176 patients were included as historical controls. The median time to achieve an undetectable viral RNA was shorter in chloroquine than in non-chloroquine (absolute difference in medians -6.0 days; 95% CI -6.0 to -4.0). The duration of fever is shorter in chloroquine (geometric mean ratio 0.6; 95% CI 0.5 to 0.8). No serious adverse events were observed in the chloroquine group. Patients treated with half dose experienced lower rate of adverse events than with full dose. CONCLUSIONS: Although randomised trials are needed for further evaluation, this study provides evidence for safety and efficacy of chloroquine in COVID-19 and suggests that chloroquine can be a cost-effective therapy for combating the COVID-19 pandemic.
has issue date	2020-05-28(xsd:dateTime)
bibo:doi	10.1093/nsr/nwaa113
has license	cc-by
sha1sum (hex)	4ef068d9f3ccad01df9c187f9858915e38557bad
schema:url	https://doi.org/10.1093/nsr/nwaa113
resource representing a document's title	Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19
has PubMed Central identifier	PMC7313782
schema:publication	Natl Sci Rev
resource representing a document's body	covid:4ef068d9f3ccad01df9c187f9858915e38557bad#body_text
is schema:about of	named entity 'COVID-19' named entity 'Preliminary' named entity 'THERAPIES' named entity 'chloroquine' named entity 'clinical study' named entity 'dizziness' named entity 'viral load' named entity 'chloroquine' named entity 'glucose' named entity 'chloroquine' named entity 'serum' named entity 'chloroquine' named entity 'Wuhan' named entity '95% CI' named entity 'significant difference' named entity '0.9' named entity '22.2' named entity 'serum' named entity 'chloroquine' named entity 'COVID' named entity 'randomised controlled study' named entity 'chloroquine' named entity 'chloroquine' named entity 'Middle East respiratory syndrome' named entity '5.4' named entity 'viral RNA' named entity '10.5' named entity 'adverse events' named entity 'chloroquine' named entity 'antiviral therapies' named entity 'serum' named entity 'chloroquine' named entity 'COVID' named entity 'stratified analysis' named entity 'gastrointestinal' named entity 'chloroquine' named entity 'Guangdong Province' named entity 'chloroquine' named entity 'antipyretic' named entity 'lipid metabolism' named entity 'nausea' named entity '95% CI' named entity 'chloroquine' named entity 'fever' named entity 'data analysis' named entity '95% CI' named entity 'inter-quartile range' named entity 'Chloroquine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software